Celgene Corporation

Celgene Corp. Q2 2008 Earnings Call Transcript

Seeking Alpha (Free subscription) | yesterday

Celgene Corporation (CELG) Q2 FY08 Earnings Call Complete Story »

Celgene Beats Targets, Guides In Line

The Street (Free subscription) | 07/24/2008

The biotech company posts earnings that are 2 cents better than Wall Street expectations.

Celgene earnings per share double in second quarter

Market Watch (Free subscription) | 07/24/2008

NEW YORK (MarketWatch) -- Celgene Corp. said Thursday that second-quarter earnings were $110.9 million, or 26 cents a share, compared to $54.9 million, or 13 cents a share, in the same period a year ago. Sales rose to $571.5 million compared to $374.9 million in the year-ago period. On average, analysts polled by FactSet Research estimated earnings per share of 33 cents. The company said total revenue...

Celgene Reports Record Second Quarter 2008 Product Sales and Operating Profits

Business Wire (Free subscription) | 07/24/2008

SUMMIT, N.J.--(BUSINESS WIRE)--2008 Second Quarter Financial Results Year-Over-Year

Earnings Preview: Celgene Corporation

Seeking Alpha (Free subscription) | 07/23/2008

Celgene Corporation (CELG) is expected to report Q2 earnings before market open Thursday, July 24, with a conference call scheduled for 9:00 a.m. ET. Guidance Analysts are expecting a profit of 35c on revenue of $538.93M. The consensus range for EPS is 31c to 38c with a revenue range of $517.55M to $561.24M, according to First Call. Positive catalysts for this earnings quarter include growing European...

MethylGene and Celgene Suspend Enrollments into Tumor Drug Study

Red Orbit (Free subscription) | 07/23/2008

MethylGene and Celgene have announced that, at the recommendation of a standing internal safety committee, the companies are temporarily suspending enrollment of new patients into clinical trials evaluating MGCD0103.

• MethylGene Inc.: MethylGene and Celgene Announce Precautionary Suspension of New Enrollments Into MGCD0103 Clinical Trials - Market Wire

MethylGene and Celgene Announce Precautionary Suspension of New Enrollments Into MGCD0103 Clinical Trials

Red Orbit (Free subscription) | 07/23/2008

MethylGene Inc. (TSX: MYG) and Celgene Corporation today announced that, at the recommendation of a standing internal safety committee, the companies are temporarily suspending enrollment of new patients into clinical trials evaluating MGCD0103.

Celgene Corporation to Announce Second Quarter 2008 Results

Business Wire (Free subscription) | 07/18/2008

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 24, 2008 at 9:00am EDT to

5-Star Stocks Poised to Pop: Celgene

Fool.com (Free subscription) | 07/11/2008

Market-trouncing returns could be written in this five-star selection.

Triple Top Breakouts Featuring Market Mover Celgene Corporation (CELG), Article by TwinTrader.com

SBWire Press Releases (Free subscription) | 07/10/2008

TwinTrader.com announces the publication of Breakout for CELG; highlighting public companies on the move and what's behind the surge.

Triple Top Breakouts Featuring Market Mover Celgene Corporation (CELG), article by TwinTrader.com

EmailWire.Com (Free subscription) | 07/10/2008

(EMAILWIRE.COM, July 10, 2008 ) DALLAS, Texas - TwinTrader.com announces the publication of Breakout for CELG; highlighting public companies on the move and what's behind the surge. Investors can view all of the Breakouts and other articles for free by visiting: http://www.TwinTrader.com “Celgene...

Biotech-Stock Mailbag: Amgen, MiddleBrook

The Street (Free subscription) | 07/04/2008

Examining Amgen's discount; updating MiddleBrook; valuing Seattle Genetics; and comparing SuperGen to Celgene.

Nasdaq 100 Leaders and Laggards: CELG UAUA

Boston Globe (Free subscription) | 07/01/2008

The Nasdaq 100 index rose Tuesday as shares of biopharmaceutical company Celgene Corp. advanced after competitor SuperGen Inc.'s bone marrow cancer drug Dacogen failed a late-stage European study.

SuperGen Bust a Boon for Celgene (Update)

The Street (Free subscription) | 07/01/2008

Dacogen's failed trial in myelodysplastic syndromes opens the door to greater market share for Celgene's Vidaza.

A Negative for SuperGen, a Plus for Celgene

The Street (Free subscription) | 07/01/2008

Dacogen failed a late-stage trial in myelodysplastic syndromes, but that's good news for the fall launch of Celgene's Vidaza.

Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy

rupali | 12/24/2007

Introduction The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson)has significantly advanced treatment. Scope...

• Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy - rupali

Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy

rupali | 12/24/2007

The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson)has significantly advanced treatment. Scope of this report...